AI is spitting out more potential drugs than ever. This start-up wants to figure out which ones matter.
10x Science raises $4.8M to use AI for identifying promising drug candidates from vast molecular datasets.
Read on TechCrunch →SpaceX is reportedly in talks to acquire AI coding startup Cursor, with an option to buy for $60 billion, highlighting the intense competition and strategic moves in the AI developer tools market.
Why it matters
This potential acquisition signifies a major strategic play by SpaceX in the rapidly evolving AI landscape. By acquiring Cursor, a company focused on AI-powered coding tools, SpaceX could be looking to integrate advanced AI capabilities into its own operations, potentially accelerating software development for its complex projects. It also highlights the immense value and competition surrounding AI startups that offer developer-centric solutions, as both Cursor and xAI are positioned against dominant AI model providers, indicating a broader trend of consolidation and strategic investment in AI infrastructure and tools.
SpaceX might buy a company called Cursor that makes AI tools for programmers. This shows how important AI is becoming for big tech companies and how much they are willing to spend to get ahead in AI.
10x Science raises $4.8M to use AI for identifying promising drug candidates from vast molecular datasets.
Read on TechCrunch →Google Cloud Next 2026 showcased numerous AI startups leveraging its cloud platform.
Read on TechCrunch →AI research lab NeoCognition secures $40 million in seed funding to develop AI agents capable of human-like learning across various domains.
Read on TechCrunch →